𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of mitoxantrone in head and neck cancer

✍ Scribed by Matti S. Aapro; Davis S. Alberts

Publisher
Springer US
Year
1984
Tongue
English
Weight
136 KB
Volume
2
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

Mitoxantrone (l,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.

πŸ“œ SIMILAR VOLUMES

Phase ii trial of etoposide and doxorubi
Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer
✍ Gradishar, William J. ;Vokes, Everett E. ;Kies, Merrill S. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 388 KB

## Abstract In an effort to improve the response rate of patients with advanced head and neck cancer, a clinical trial combining two infrequently studied drugs was conducted. Twelve patients with squamous cell carcinoma of the head and neck were treated with 3‐day continuous infusions of etoposide

A phase II study of mitoxantrone in adva
A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck
✍ H. Wheeler; R. L. Woods; J. Page; J. Levi πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 186 KB

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two